Shield Therapeutics plc (LON:STX)
6.10p
Spriggl Score: Moderate— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Forty-four percent prescription growth masks milestone-inflated profits; negative equity and Medicaid headwinds threaten the path to self-funding.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the …
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - Specialty & Generic
- Market Cap:
- £66.3M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Shield Therapeutics plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free